Siddharth Kaul, MD
Neurology · Bridgeton, MONPI 1245493402
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $351,434 of the $386,826 with a category attached, or 90.9%. AbbVie accounts for 79.3% of it on its own, with 26 other manufacturers making up the rest. Among neurology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 984 payments — averaging $393.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$307K
- Eisai Inc.$31K
- Biohaven Pharmaceuticals, Inc.$21K
- Pfizer$11K
- Axsome Therapeutics, Inc.$7K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- plus $4K from 21 others
Across 293 payments — averaging $18,331 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4.4M
- H. Lundbeck A S$238K
- Pfizer$159K
- Sage Therapeutics, LLC$135K
- Acadia Pharmaceuticals Inc$134K
- Avanir Pharmaceuticals, Inc.$109K
- plus $237K from 6 others
What the payments were for
- Consulting fees$9830%
- Speaking & faculty fees$351,43491%
- Travel & lodging$13,2763%
- Food & beverage$21,0785%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 693 | $306,779 |
| Eisai Inc. | 48 | $31,205 |
| Biohaven Pharmaceuticals, Inc. | 43 | $21,102 |
| Pfizer | 91 | $10,602 |
| Axsome Therapeutics, Inc. | 10 | $6,839 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $6,147 |
| Neurocrine Biosciences, Inc. | 20 | $695 |
| AstraZeneca | 5 | $618 |
| SK Life Science, Inc. | 8 | $489 |
| Biogen | 9 | $441 |
| E.r. Squibb & Sons, L.L.C. | 5 | $400 |
| Genentech USA, Inc. | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 3 | $209 |
| Bristol Myers Squibb | 5 | $137 |
| TG Therapeutics, Inc. | 1 | $136 |
| MDD US Operations, LLC | 2 | $128 |
| Greenwich Biosciences, Inc. | 1 | $126 |
| Averitas Pharma Inc. | 1 | $105 |
| Sunovion Pharmaceuticals Inc. | 1 | $88 |
| Novartis | 5 | $81 |
| Merck | 2 | $68 |
| Upsher-smith Laboratories LLC | 2 | $51 |
| Lundbeck LLC | 2 | $45 |
| EMD Serono, Inc. | 2 | $29 |
| Lilly USA, LLC | 2 | $25 |
| Johnson & Johnson | 1 | $19 |
| Assertio Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$386,826 in reported general payments places this provider in the 95th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TecfideraDimethyl Fumarate | 11 | $101,289 |
| Nurtec OdtRimegepant Sulfate | 48 | $80,124 |
| UbrelvyUbrogepant | 55 | $73,191 |
| CopaxoneGlatiramer Acetate | 13 | $72,849 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $51,450 |
| QuliptaAtogepant | 46 | $49,044 |
| EpidiolexCannabidiol (Cbd) | 20 | $39,895 |
| BriviactBrivaracetam | 17 | $31,778 |
| Emgality PenGalcanezumab-Gnlm | 37 | $31,423 |
| Dimethyl Fumarate | 21 | $9,797 |
| Lacosamide | 71 | $8,787 |
| Gabapentin | 232 | $4,094 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 131 | $3,659 |
| Levetiracetam | 113 | $3,195 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 128 | $3,024 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $306,779 | $122,235101 claims |
| BiogenTecfidera | $441 | $101,28911 claims |
| PfizerNurtec Odt, Dilantin | $10,602 | $82,45765 claims |
| Upsher-smith Laboratories LLCTopiramate | $51 | $77571 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 381 neurology providers in Missouri.
Other neurology in Bridgeton
- Daniel MattsonBridgeton$451K
- Seth HepnerBridgeton$285K
- Xinrong LuBridgeton$24K
- William RosenfeldChesterfield$2.1M
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Curtis SchreiberBolivar$882K
- Robert NaismithSaint Louis$677K
- Barbara GreenChesterfield$352K
- Steven KosaNorth Kansas City$323K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.